SynthesisCancer medicine2025
The Survival Benefits of Chemotherapy for Undifferentiated Carcinoma With Osteoclast-Like Giant Cells of Pancreas: A Retrospective Analysis and Individual Participant Data Meta-Analysis.
Synthesis in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Undifferentiated Carcinoma with Osteoclast-Like Giant Cells Associated with CarcinomaSurgical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimUndifferentiated carcinoma with osteoclast-like giant cells of pancreas (UCOGCP) is a rare type of pancreatic adenocarcinoma (PDAC). However, the efficacy of chemotherapy in UCOGCP has not been evaluated so far due to the scarcity of cases. This study aims to evaluate the efficacy of chemotherapy in UCOGCP combined with previous individual participant data (IPD) and SEER database data.
methodsForty-nine patients with UCOGCP were enrolled from the Surveillance, Epidemiology, and End Results (SEER) database. Based on whether they had received chemotherapy or not, we divided UCOGCP patients into chemotherapy group (N = 32) and non-chemotherapy group (N = 17). The survival time of the chemotherapy group and non-chemotherapy group was assessed by Kaplan-Meier analysis and Cox analysis. IPD data for UCOGCP were collected in PubMed, Embase, Cochrane, and ScienceDirect. The results based on the SEER database were verified by IPD meta-analysis.
resultsThe Kaplan-Meier analysis indicated that patients who received chemotherapy experienced a longer survival time compared to those who did not (OS: p = 0.00061, CSS: p = 0.00047). Univariate (OS: HR: 0.31 [0.15, 0.63], p = 0.001; CSS: HR: 0.28 [0.13, 0.60], p = 0.001) and multivariate (OS: HR: 0.33 [0.14, 0.78], p = 0.012; CSS: HR: 0.30 [0.12, 0.73], p = 0.008) Cox regression showed that chemotherapy was the independent prognostic protective factor for UCOGCP. IPD meta-analysis showed that chemotherapy can significantly improve the prognosis of patients who received primary tumor resection (PTR, p = 0.0084).
conclusionIn contrast to not receiving chemotherapy, chemotherapy is effective in prolonging survival in UCOGCP patients with or without PTR. This provides a foundation for the use of UCOGCP chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.